HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Clear cell sarcoma — Clinical Guidelines

Overview

Clear cell sarcoma (CCS) is a rare and aggressive soft tissue malignancy characterized by high metastatic potential and recurrence rates, often necessitating improved therapeutic strategies beyond conventional treatments 1.

Diagnosis

Histogenesis: CCS originates from neural crest cells, as indicated by the presence of S-100 protein in both amelanotic and melanotic variants 2.

Electron Microscopy and Biochemical Studies: Utilize glycosaminoglycan analysis and DOPA reaction to differentiate from synovial sarcoma, though both amelanotic and melanotic CCS show similarities 2.

Immunohistochemistry: S-100 protein positivity is a consistent marker across CCS subtypes 2.

Management

Immunotherapy: Development of multi-epitope vaccines and mRNA-based vaccines targeting EWSR1-ATF1, EWSR1-CREB1 fusion proteins, and PRAME antigen to enhance immune responses 1.

Novel Vaccine Approaches: Incorporation of GM-CSF in multi-epitope vaccine constructs and codon optimization in mRNA vaccines to improve efficacy and safety 1.

Special Populations

No Specific Data: Abstracts do not provide specific guidance on management in pregnancy, pediatrics, elderly, or patients with comorbidities 1 2.

Key Recommendations

Consider novel multi-epitope and mRNA-based vaccine strategies targeting specific fusion proteins and PRAME antigen for enhanced immunotherapy in CCS patients (Evidence: Expert opinion) 1.

Utilize S-100 protein immunohistochemistry as a consistent marker for diagnosing CCS across different subtypes (Evidence: Moderate) 2.

Further research is needed to establish specific management guidelines for CCS in special populations such as pediatric patients, elderly individuals, and those with comorbidities (Evidence: Expert opinion) 1 2.

References

1 Yaseen AR, Suleman M, Alzahrani KJ, Alsharif KF, Alzahrani FM. Unleashing the future of cancer immunotherapy: in silico design of a multi-epitope and mRNA vaccine duo targeting EWSR1-ATF1, EWSR1-CREB1, and PRAME to conquer clear cell sarcoma using immunoinformatics approaches. Medical oncology (Northwood, London, England) 2025. link 2 Mukai M, Torikata C, Iri H, Mikata A, Kawai T, Hanaoka H et al.. Histogenesis of clear cell sarcoma of tendons and aponeuroses. An electron-microscopic, biochemical, enzyme histochemical, and immunohistochemical study. The American journal of pathology 1984. link

Clear cell sarcoma